Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 19/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30166844 | 1.00 | QPCT (0.41) | QPCTROCK2PIM1GSK3BAURKB | |
| SCHEMBL24816696 | 1.00 | QPCT (0.41) | QPCTROCK2PIM1GSK3BAURKB | |
| SCHEMBL26833344 | 1.00 | QPCT (0.41) | QPCTROCK2PIM1GSK3BAURKB | |
| SCHEMBL24815787 | 1.00 | QPCT (0.41) | QPCTROCK2PIM1GSK3BAURKB | |
| SCHEMBL25708373 | 0.96 | QPCT (0.39) | QPCTROCK2PIM1GSK3BAURKB | |
| SCHEMBL24815390 | 0.84 | QPCT (0.42) | QPCT | |
| SCHEMBL30166764 | 0.84 | QPCT (0.42) | QPCT | |
| SCHEMBL24814385 | 0.84 | QPCT (0.42) | QPCT | |
| SCHEMBL24816713 | 0.84 | QPCT (0.42) | QPCT | |
| SCHEMBL25708377 | 0.80 | QPCT (0.41) | QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118019737-A | Beta-lactam derivatives for the treatment of diseases | 英矽智能科技知识产权有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-11834440-B2 | Beta-lactam derivatives for the treatment of diseases | INSILICO MEDICINE IP LIMITED (HK) | 2023-12-05 | — | — | US | disclosed |
| US-11834440-B2 | Beta-lactam derivatives for the treatment of diseases | INSILICO MEDICINE IP LIMITED (HK) | 2023-12-05 | — | — | US | disclosed |
| US-20230192667-A1 | BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-22 | — | — | US | disclosed |
| WO-2022268179-A1 | BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES | INSILICO MEDICINE IP LIMITED (CN) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192667-A1 | BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES | QPCT, QPCTL, BCAT1 | QPCT 1/4885ROCK2 3930/4885PIM1 3414/4885 |
| US-11834440-B2 | Beta-lactam derivatives for the treatment of diseases | QPCT, QPCTL, BCAT1 | QPCT 1/4885ROCK2 3930/4885PIM1 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.